Figure 5.
Adoptive T cell therapy with anti-gp100 CD8+ TCR transgenic T cells in the HCC model
(A) The HCC model was treated as early as 2 days after hydrodynamic injection of the plasmids with preactivated pmel-1 T cells as indicated. Mice were monitored for tumor burden by bioluminescence, and survival was recorded.
(B) Time course of bioluminescence (median ± 95% CI) of the indicated groups of mice. As a specificity control, a group of mice received pmel-1 transfer without prior gp100 in the plasmid mixture for hydrodynamic gene transfer.
(C) Corresponding bioluminescence images.
(D) Overall survival of the experimental treatment groups of mice.
(E) Similar experimental setting as in (A) but postponing T cell transfer until day 14 post-hydrodynamic injection. In this case, a group of mice received control TCR transgenic T cells that recognize an irrelevant antigen in this model (OT1 T cells that recognize an ovalbumin H2-Kb-presented epitope).
(F and G) Bioluminescence quantification (median ± 95% CI) and images recorded at the indicated time points.
(H) Survival follow-up of the treated mice (number of mice and survival median are provided for each group of mice).